This activity offers CE credits for:
1. Physicians (CME)
All other clinicians either will receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
The goal of this activity is to inform readers about the possible connections between infertility and mental health disorders.
Understand the prevalence of mood and anxiety disorders in women experiencing infertility and undergoing infertility treatment
Identify patients who may need psychiatric support during infertility treatment
Appreciate factors that may modulate vulnerability to stress, anxiety, and depression in the context of infertility and its treatment
Identify appropriate treatment options for mood and anxiety disorders in women undergoing infertility treatment
This continuing medical education (CME) activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve the care of patients with mental health disorders.
ACCREDITATION/CREDIT DESIGNATION/FINANCIAL SUPPORT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians Education Resource, LLC and Psychiatric TimesTM. Physicians Education Resource, LLC is accredited by ACCME to provide continuing medical education for physicians.
Physicians Education Resource, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is funded entirely by Physicians Education Resource, LLC. No commercial support was received.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patients medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians Education Resource, LLC.
FACULTY, STAFF, AND PLANNERS DISCLOSURES
Elizabeth Clayton, Ruta Nonacs, MD, PhD, Linda L.M. Worley, MD, FACLP (external reviewer), the staff members of Physicians Education Resource, LLC, and Psychiatric TimesTM have no relevant financial relationships with commercial interests.
HOW TO CLAIM CREDIT
Once you have read the article, please use the following URL to evaluate and request credit https://education.gotoper.com/activity/ptcme20dec. If you do not already have an account with PER you will be prompted to create one. You must have an account to evaluate and request credit for this activity.
Ms Clayton is an MD candidate (class of 2021) at Tufts University School of Medicine. Dr Nonacs is clinical assistant professor in the Department of Psychiatry at Massachusetts General Hospital and editor in chief at the MGH Center for Womens Mental Health.
Difficulty with conceiving can have many psychological repercussions. Infertility is defined as the inability of a couple to conceive after 12 months of regular intercourse without the use of contraception in women aged 35 years or younger, or after 6 months in women aged 36 years or older. The Centers for Disease Control and Prevention (CDC) reports that 12% of women aged 15 to 44 years have difficulty getting pregnant or carrying a pregnancy to term (Figure). Some form of infertility was reported by 9% of men aged 25 to 44 years. In about 35% of couples surveyed, infertility was due to both male and female factors.1
Infertility can have a profound impact on psychological well-being for both the individual and the couple. A woman may find herself feeling betrayed by her body and may be overcome by emotions, ranging from profound despair to anger and resentment, when a friend announces a pregnancy. Sexual intimacy can morph from an expression of closeness to a demand for conception. Each failed cycle is a multifaceted burden. In vitro fertilization (IVF) is rarely covered by insurance. Some individuals may even become suicidal with recurrent loss of pregnancy.
While we acknowledge that infertility and its treatment are physically and psychologically challenging, there is a paucity of research into the association between psychiatric illness and infertility (Table 1). Additionally, we know little about the psychological impact of infertility and prolonged exposure to infertility treatment on mood and well-being. As the current research stands, it is unclear how mood and anxiety disorders impact fertility and if infertility and its treatment may lead to mood and anxiety disorders.
Impact of affective disorders on fertility and its treatment
There are conflicting data regarding the impact of depression and anxiety on the reproductive cycle. In one study, it was observed that depressive symptoms were not associated with changes in reproductive hormone levels,2 but other studies have found that self-reported levels of stress do impact hormone levels.3 In a group of young women aged 17 to 20 years,higher ratings of stress were associated with lower estradiol (but not testosterone or progesterone) concentrations. This finding is consistent with previous studies suggesting that prolonged perceived stress may lower overall estradiol production, thus inhibiting ovulation and suppressing reproduction.
Inflammation may also play an important role in infertility, and current research suggests that chronic inflammation may affect fertility and pregnancy outcomes. Chronic stress, depression, and anxiety have all been associated with inflammation and, therefore, may interfere with attempts to conceive. In a study of women and men undergoing infertility treatment, higher stress levels were associated with various markers of inflammation, including higher cervicovaginal inflammatory cytokines. These inflammatory markers were, in turn, associated with a decreased likelihood of achieving pregnancy through IVF.4
It is likely that high levels of cumulative stress associated with recurrent depression and/or anxiety may affect multiple stages of fertilization. That said, normal levels of stress related to infertility treatment probably have minimal effects. A prospective study from Donarelli and colleagues5 examined anxiety and stress levels in women and men pursuing infertility treatment before undergoing ovarian stimulation. The researchers found that neither partners level of treatment-related stress had an impact on the number of ovarian follicles greater than 16 mm, with ovarian follicle size being a predictor of IVF success.
Health care providers can reassure patients that neither partners situational stress will impact follicle stimulation. Additionally, it has been speculated that chronic stress impedes successful implantation, but difficulty with implantation can be overcome using IVF. Although more research is needed, IVF may be a reasonable recommendation for women with mood disorders who are experiencing infertility.6
Although it is unclear whether depression affects fertility, it may have an impact on treatment with assisted reproductive technology (ART). Health care providers should be aware that women with depression are less likely to pursue infertility treatment. A recent prospective study of patients attending a fertility clinic found that women who screened positive for depression were about half as likely to initiate treatment for infertility compared with their nondepressed counterparts.7 Additionally, depression in women has been associated with higher ART dropout rates. One study found that couples with a clinically depressed female partner were 5 times more likely to discontinue treatment than couples with a nondepressed partner.8 Screening for depression is therefore important in couples pursuing infertility treatment, and extra care should be taken to provide appropriate support to patients seeking infertility treatment who screen positive for an affective disorder.
Eating disorders and infertility treatment
Infertility and subfertility may occur in women with anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED). In women with active illness, amenorrhea and oligomenorrhea can compromise the likelihood of conception (Table 2). Menstrual irregularities occur most commonly in women with AN, with 39% to 42% experiencing amenorrhea (an absence of menstruation) and an additional 6% to 11% reporting oligomenorrhea (infrequent menstruation); however, 7% to 40% of women with BN report amenorrhea and 36% to 64% experience oligomenorrhea.9
The strongest predictors of amenorrhea in women with eating disorders are low body mass index (BMI), low caloric intake, and higher levels of exercise. Weight restoration is the primary intervention for amenorrhea in women with eating disorders, although amenorrhea may persist even after normal weight has been restored.In addition, polycystic ovarian syndrome (PCOS) may be another factor contributing to menstrual irregularity in this population, as PCOS is common among women with BN and BED. In fact, one study reported polycystic ovaries in 75% of women with BN.9
Women with a current eating disorder may experience fertility problems, especially if they have a low BMI and experience menstrual irregularity. However, data regarding the fertility of women with a history of an eating disorder have yielded mixed results.Many studies, including 2 large, population-based cohort studies, have demonstrated similar rates of successful pregnancy in women with a history of an eating disorder compared with women in the general population.10 At the same time, prospective data from the Avon Longitudinal Study of Parents and Children (ALSPAC) indicate that women with a history of AN or BN were more likely to take longer than 6 months to conceive and were more likely to have conceived with the aid of fertility treatment.11
While we do not have detailed information on the impact of other psychiatric disorders (such as bipolar disorder and schizophrenia) on fertility, it should be noted that certain medications used to treat these disorders may cause menstrual irregularities, including amenorrhea, and may thus negatively affect fertility. For example, antipsychotic agents with strong antagonism of the dopamine D2 receptor, such as risperidone and older antipsychotics, increase levels of prolactin, causing hypogonadotropic hypogonadism and subsequent menstrual dysfunction.12
Finally, drug and alcohol use disorders have well-documented effects on the fetus, but the effects on conception and implantation of an embryo are unclear. Studies have suggested that substance use disorder has a negative impact on female and male fertility, but more research is needed in this area.13 The majority of data have come from animal models. Studies in humans have been observational and are complicated by participants who use multiple substances and different routes of administration. Explicit associations between substance use and fertility is further confounded by lifestyle factors that often accompany substance use, such as overall unhealthy lifestyle, poor decision-making, and comorbid physical and mental health disorders.14
Psychological impact of fertility treatment
The decision to begin ART can be very stressful for couples, and research has shown that stress may increase with each subsequent fertility treatment.15 However, distress can manifest at any point during ART. In a large Dutch study following couples experiencing infertility (who reported undergoing an average of 4.3 fertility treatments over 5 years), a passive-avoidant method of coping (eg, hoping for a miracle) was linked with psychological distress in women, and this effect increased over time. For men, this coping style led to increased marital distress.16 Women who perceived infertility as central to their identity, and who were resistant to realigning their goals, reported greater distress during fertility treatment.17 On the other hand, meaning-based coping strategies, learning to grow from a negative experience, and/or finding other goals in life were associated with decreased distress in women, but not in men. A womans use of meaning-based coping strategies also decreased marital stress for both partners.16 It is important to note that these studies are based in countries where fertility treatment is covered by insurance, which is rare in the United States. American couples undergoing ART have additional stressors, although they would also likely benefit from these coping strategies.
Protective factors have also been identified. For a woman, having a higher level of education and adequate social supports decreases distress during ART. For men, a problem-solving coping strategy was linked to a higher self-reported quality of life (QOL).15 In a study from Israel, where there is a social emphasis on having children, researchers observed that maintaining daily routines and making efforts to feel normal led to a higher QOL and better adjustment to fertility treatment.18 In another study, the Dyadic Adjustment Scale (DAS), a tool that measures relationship distress, was administered to couples currently undergoing fertility treatment. Higher dyadic adjustment was associated with better QOL and less psychological distress in both men and women undergoing ART. However, this protective effect was diminished when infertility persisted for longer than 3 years.15
Although multiple studies have assessed psychological distress in couples undergoing treatment for infertility, far fewer have assessed the prevalence of clinically significant anxiety and depressive symptoms in this population. A large Danish study of couples undergoing ART found severe depressive symptoms in 11.6% of women and 4.3% of men.19 These symptoms correlated to an increase in infertility-related distress. However, there is considerable variation among studies with regard to rates of depression and anxiety in couples pursuing infertility treatment, which may reflect differences in type of ART, duration of infertility, number of failed cycles, cultural considerations, and methods used to assess symptoms.
According to another study, women who conceived through ART showed no difference in anxiety and depressive symptoms compared with pregnant women who conceived naturally. However, rates of depression and anxiety were higher in subfertile, nonpregnant women (57.6% and 15.7%, respectively).20 Comparisons between women undergoing repeated IVF cycles and first-time participants have suggested that ongoing treatment may lead to an increase in depressive symptoms, which may persist for 6 months after a failed ART trial.21
Recent research also suggests that both women and men with a history of major depressive disorder (MDD) are more likely to experience depressive symptoms during ART.22 In a prospective observational study of 25 women with a history of MDD undergoing ART, 44% of the women experienced a depressive relapse; rates of relapse were similar among women who maintained antidepressant use compared with those who discontinued treatment.23
In another study, researchers observed that among 108 women undergoing IVF for the first time, those with a history of unipolar depression or anxiety disorder reported more depressive symptoms than controls without these disorders. The group without psychiatric illness responded to fertility treatment with elevated cortisol levels (compared to baseline), whereas women with a history of mood or anxiety disorder had a blunted cortisol response. These results may indicate that infertile women with Axis I disorders may have chronically elevated levels of cortisol, even before entering into infertility treatment.24
Steps should be taken to screen couples, not just women, for psychiatric disorders and chronic stress prior to beginning infertility treatment, as well as throughout treatment. Although depressive symptoms and anxiety occur frequently in women experiencing infertility, many women do not seek treatment. In fact, many women resist disclosing their mental health status to their reproductive endocrinologist for fear that they would be deemed bad candidates for infertility treatment. Effectively treating eating disorders, substance use disorders (including alcohol and tobacco use), and bipolar disorder from the initiation of infertility treatment will aid in a healthy pregnancy, if conception is successful.
Although there is no evidence to suggest that antidepressants or anxiolytic medications negatively affect fertility or infertility treatment, many women are reluctant to use medication in this setting. Women undergoing infertility treatment may not engage in treatment of anxiety and depression because they already feel overburdened by the demands of infertility treatment on their time and financial resources. In addition, having to pursue psychiatric treatment in this setting may accentuate the shame and stigma many women with infertility often feel.
Providing couples with information normalizes the psychological effects of infertility and its treatment may help patients adjust to and tolerate the process. Clinicians should give guidance when psychological symptoms are more than a normal reaction to a common reaction to failed ART. Counseling patients on the importance of self-care, healthy coping strategies, and improving communication may have a positive impact on both the individual and couple. Patient support can include connecting them with community support resources, such as RESOLVE (a network of groups affiliated with the National Infertility Association), and recommending a consultation with a sex therapist to help the couple maintain a positive connection with each other.
Additionally, targeted psychological interventions may help alleviate the adverse psychological outcomes associated with infertility and its treatment, including anxiety, depressive symptoms, and marital stress (Table 3). According to a recent meta-analysis25 that included 39 studies and a total of 3064 women and 347 men, psychological interventions, most commonly cognitive behavioral therapy (CBT) or mind-body interventions (MBI), may be effective for reducing anxiety (25 studies), as well as depressive symptoms (21 studies). These interventions also appeared to improve rates of pregnancy; in this meta-analysis, women treated with CBT or MBI were about twice as likely to achieve pregnancy compared with women receiving usual care. Of note, larger reductions in anxiety were associated with greater improvements in pregnancy rates.
To date, there is no research that specifically looked at the pharmacologic treatment of depression or anxiety in women with infertility. Thus, the same principles that guide the treatment of women during pregnancy should inform the treatment of women undergoing infertility treatment. There are sufficient data to support the use of selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs and SNRIs), bupropion, and tricyclic antidepressants. Other factors that may influence the selection of an antidepressant include prior response to a particular antidepressant, comorbidity of anxiety symptoms, and adverse effect profile.
Benzodiazepines, including lorazepam and clonazepam, may be helpful for the management of anxiety disorders, treatment-emergent anxiety, and sleep disturbance. Althoughearlier reports suggested an increased risk of cleft lip and palate associated with prenatal benzodiazepine exposure, more recent reports have shown no increase in the overall risk of malformations in children exposed to benzodiazepines during pregnancy.26
Many women question whether the use of these medications may affect fertility or the success of infertility treatment. Although there is no evidence to indicate that antidepressants or benzodiazepines have deleterious effects on fertility, this has not been studied systematically. There have been reports suggesting a small but statistically significant increase in risk of miscarriage in women treated with SSRIs, although this is not a universal finding.27 It is also important to note that women who suffer from mood and anxiety disorders probably carry a slightly higher risk of miscarriage. In fact, women with a history of depression who stop treatment with an antidepressant 3 to 12 months prior to conception have the same risk of miscarriage as women who continue treatment with an antidepressant.28
Although avoiding treatment with a medication may seem like the safest option, untreated anxiety and/or depression in the mother has been associated with negative pregnancy outcomes, including increased risk of preterm birth, low birth weight, and other complications.29 In addition, depression during pregnancy is a robust predictor of postpartum depression. Numerous somatic complaints are treated with medication during pregnancy; psychological complaints can be just as detrimental and should be treated, as well.
Infertility is a common and psychologically distressing experience, both for the individual and the couple. Although there is a dearth of research examining the association between infertility and psychiatric illness, preliminary research indicates that depression, anxiety, and chronic stress may contribute to inflammation and alterations in hormone levels, factors which may affect the likelihood of successful pregnancy outcomes. Additionally, ongoing infertility treatment has been linked to increased depressive symptoms and anxiety and may hinder couples ability to pursue and continue with infertility treatment.As noted, eating disorders can also affect fertility.
Increased psychological support during infertility treatment would be beneficial for this population and may improve the chances of a successful pregnancy. The patient undergoing infertility treatment should be given the same plan of care as any patient with anxiety or depression. Support should include expectation management around the psychological effects of infertility treatment, as well as promotion of healthy coping strategies, such as taking time for self-care. If needed, pharmacotherapy with SSRIs or benzodiazepines is unlikely to have an adverse effect on conception and may decrease ART dropout. However, more research is needed to establish the connection between psychological illness and depression in order to create effective targeted therapies.
PLEASE NOTE THAT THE POSTTEST IS AVAILABLE ONLINE ONLY ON THE 20TH OF THE MONTH OF ACTIVITY ISSUE AND FOR 18 MONTHS AFTER.
1. Reproductive Health: Infertility FAQs. Centers for Disease Control and Prevention. Updated January 16, 2019. Accessed November 7, 2019. https://www.cdc.gov/reproductivehealth/infertility/index.htm
2. Prasad A, Schisterman EF, Schliep KC, et al. Depressive symptoms and their relationship with endogenous reproductive hormones and sporadic anovulation in premenopausal women. Ann Epidemiol. 2014;24(12):920-924.
3. Roney JR, Simmons ZL. Elevated psychological stress predicts reduced estradiol concentrations in young women. Adapt Human Behav Physiol. 2015;1(1):30-40.
4. Haimovici F, Anderson JL, Bates GW, et al. Stress, anxiety, and depression of both partners in infertile couples are associated with cytokine levels and adverse IVF outcome. Am J Reprod Immunol. 2018;79(4).
5. Donarelli Z, Lo Coco G, Gullo S, et al. Infertility-related stress, anxiety and ovarian stimulation: can couples be reassured about the effects of psychological factors on biological responses to assisted reproductive technology? Reprod Biomed Soc Online. 2016;(3):16-23.
6. Zaig I, Azem F, Schreiber S, et al. Womens psychological profile and psychiatric diagnoses and the outcome of in vitro fertilization: is there an association? Arch Womens Ment Health. 2012;15(5):353-359.
7. Crawford NM, Hoff HS, Mersereau JE. Infertile women who screen positive for depression are less likely to initiate fertility treatments. Hum Reprod. 2017;32(3):582587.
8. Pedro J, Sobral MP, Mesquita-Guimares J, . Couples discontinuation of fertility treatments: a longitudinal study on demographic, biomedical, and psychosocial risk factors. J Assist Reprod Genet. 2017;34(2):217-224.
9. Kimmel MC, Ferguson EH, Zerwas S, Bulik CM, Meltzer-Brody S. Obstetric and gynecologic problems associated with eating disorders.Int J Eat Disord. 2016;49(3):260-275.
10. Tabler J, Utz RL, Smith KR, Hanson HA, Geist C. Variation in reproductive outcomes of women with histories of bulimia nervosa, anorexia nervosa, or eating disorder not otherwise specified relative to the general population and closest-aged sisters.Int J Eat Disord. 2018;51(2):102111.
11. Schmidt U, Sharpe H, Bartholdy S, et al. Treatment of anorexia nervosa: a multimethod investigation translating experimental neuroscience into clinical practice. Programme Grants Appl Res. 2017;5(16):95-107.
12. Lania A, Gianotti L, Gagliardi I, Bondanelli M, Vena W, Ambrosio MR. Functional hypothalamic and drug-induced amenorrhea: an overview. J Endocrinol Invest. 2019;42(9):1001-1010.
13. Sansone A, Di Dato C, de Angelis C, et al. Smoke, alcohol and drug addiction and male fertility.Reprod Biol Endocrinol. 2018;16(1):3.
14. de Angelis C, Nardone A, Garifalos F, et al. Smoke, alcohol and drug addiction and female fertility.Reprod Biol Endocrinol. 2020;18(1):21.
15. Zurlo MC, Cattaneo Della Volta MF, Vallone F. Predictors of quality of life and psychological health in infertile couples: the moderating role of duration of infertility. Qual Life Res. 2018;27(4):945-954.
16. Peterson BD, Pirritano M, Christensen U, et al. The longitudinal impact of partner coping in couples following 5 years of unsuccessful fertility treatments. Hum Reprod. 2009;24(7):1656-1664.
17. Neter E, Goren S. Infertility centrality in the womans identity and goal adjustment predict psychological adjustment among women in ongoing fertility treatments. Int J Behav Med. 2017;24(6):880-892.
18. Benyamini Y, Gozlan M, Weissman A. Normalization as a strategy for maintaining quality of life while coping with infertility in a pronatalist culture. Int J Behav Med. 2017;24(6):871-879.
19. Peterson BD, Sejbaek CS, Pirritano M, Schmidt L. Are severe depressive symptoms associated with infertility-related distress in individuals and their partners? Hum Reprod. 2013;29(1):76-82.
20. Joelsson LS, Tydn T, Wanggren K, et al. Anxiety and depression symptoms among sub-fertile women, women pregnant after infertility treatment, and naturally pregnant women. Eur Psychiatry. 2017;45:212-219.
21. Milazzo A, Mnatzaganian G, Elshaug AG, et al. Depression and anxiety outcomes associated with failed assisted reproductive technologies: a systematic review and meta-analysis. PLoS ONE. 2016;11(11): e0165805.
22. Holley SR, Pasch LA, Bleil ME, et al. Prevalence and predictors of major depressive disorder for fertility treatment patients and their partners. Fertil Steril. 2015;103(5):1332-1339.
23. Freeman MP, Lee H, Savella GM, et al. Predictors of depressive relapse in women undergoing infertility treatment. J Womens Health. 2018;27(11):1408-1414.
24. Zaig I, Azem F, Schreiber S, et al. Psychological response to cortisol reactivity to in vitro fertilization treatment in women with a lifetime anxiety or unipolar mood disorder diagnosis. J Clin Psychiatry. 2013;74(4):386-92.
25. Frederiksen Y, Farver-Vestergaard I, Skovgrd NG, et al. Efficacy of psychosocial interventions for psychological and pregnancy outcomes in infertile women and men: a BMJ Open. 2015;5(1):e006592.
26. Andersen JT, Andersen NL, Horwitz H, et al. Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage. Obstet Gynecol. 2014;124(4):665-61.
27. Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis. J Clin Psychiatry. 2019;80(4).
28. Jarde A, Morais M, Kingston D, et al. Neonatal outcomes in women with untreated antenatal depression compared with women without depression: a systematic review and meta-analysis. JAMA Psychiatry. 2016;73(8):826-837.
29. Wu P, Velez Edwards DR, Gorrindo P, et al. Association between first trimester antidepressant use and risk of spontaneous abortion. Pharmacotherapy. 2019;39(9):889-898.
Read the original post:
The Intertwining Effect of Mood Disorders and Infertility - Psychiatric Times
- Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report - DocWire News - December 27th, 2020
- Global Veterinary Therapeutics Market to reach USD 54968.3 Million with 5.8% CAGR by 2025 on Account of Rising R&D Activities, states Fortune Business... - December 12th, 2020
- Global Hormone Replacement Therapy Market To Witness Huge Gains Over 2020-2026 - Tri-City Tribune - December 12th, 2020
- Male Hypogonadism Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - The Market Feed - December 3rd, 2020
- Male Hypogonadism Therapy Market Size, Key Manufacturers, Demand, Application And Opportunities By 2027 - The Haitian-Caribbean News Network - December 3rd, 2020
- Male Hypogonadism Market is Expected to Thrive at Impressive CAGR by 2026 & Top Key Players are Astrazeneca Plc., Merck& Co. Inc.,... - December 3rd, 2020
- Estrogen in men: Symptoms of high and low levels, and more - Medical News Today - November 11th, 2020
- Male Hypogonadism Market Projected to be Resilient During 2025 - The Market Feed - November 11th, 2020
- Male Hypogonadism Therapy Market Forecast to 2027: Top Companies, Trends & Growth Factors and Trend Forecast to 2027 - TechnoWeekly - November 9th, 2020
- China Male Hypogonadism Market: Latest Trends, Demand and Analysis 2025 - The Think Curiouser - November 9th, 2020
- Global Hypogonadism Drug Market Business Share, Industry Size and Future Investment Opportunities by 2026||ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly... - November 9th, 2020
- Aytu BioScience to Report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020 - Yahoo Finance - November 9th, 2020
- Testosterone Replacement Therapy Market | Latest Trends and Revenues Analysis Report - BioSpace - November 1st, 2020
- EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi and Submits Market... - October 22nd, 2020
- Male Hypogonadism Therapy Market is Booming Worldwide By Top Key Players: Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - October 17th, 2020
- Share tips of the week - MoneyWeek - October 17th, 2020
- Harvard Study Shows That Flavonoids Could Prevent Erectile Dysfunction - Gilmore Health News - October 17th, 2020
- Latest Report By QYResearch on Hormone Replacement Therapy (HRT) Market Trend, Overview, Competitor Analysis, Growth by 2026 - Weekly Wall - October 9th, 2020
- Covid-19 could lower testosterone levels and libido in men - heres what the new study found - Derry Journal - October 9th, 2020
- Sperm Take Up to 3 Years to Recover After Anabolic Steroids - Medscape - October 3rd, 2020
- Covid-19 could lower testosterone levels and libido in men - heres what the new study found - Shields Gazette - October 3rd, 2020
- Treatment of the infertile couple - Contemporary Obgyn - October 3rd, 2020
- Impact of COVID-19 on Global Testosterone undecanoate Market Size, Share, Segmentations and Forecast 2025 by Industry Key Players, Solutions and... - October 3rd, 2020
- Consumers Opting For To Help The Male Hypogonadism Market Cross US$ 3,300 Mn Between 2026 - industrytoday.co.uk - September 25th, 2020
- Testosterone boosters: Uses and effectiveness - Medical News Today - September 22nd, 2020
- Aytu BioScience to Report Fourth Quarter FY 2020 Results and Business Update on Thursday, September 24, 2020 - Yahoo Finance - September 22nd, 2020
- Male Hypogonadism Therapy Market with Future Prospects, Key Player SWOT Analysi - News by aeresearch - September 11th, 2020
- Hypergonadism: Symptoms, Causes, Treatment, and More - September 11th, 2020
- Male Hypogonadism Market To Witness A CAGR Of 3.7% Between 2026 - Bulletin Line - September 7th, 2020
- Covid-19 Impact on Global Testosterone Cypionate Market by Product Type, With Production, Revenue, Price, Industry Share and Growth Rate, Analysis... - September 7th, 2020
- Vogelzang Discusses Treatment Choices for mCRPC in the Frontline and Beyond - Targeted Oncology - August 31st, 2020
- Hormone Replacement Therapy Market: Rising incidences of hormonal imbalance disorders is the primary drivers of this market - BioSpace - August 31st, 2020
- International honour for Sheffield pioneer of therapy for children with chronic hormone deficiency - indiaeducationdiary.in - August 29th, 2020
- LPCN: Tlando: Target Action Date This Friday - Zacks Small Cap Research - August 25th, 2020
- UB diabetes expert's research shows testosterone therapy can lead to remission in men with Type 2 diabetes - UB News Center - July 30th, 2020
- Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration - Yahoo Finance - July 30th, 2020
- What is Male Menopause? Heres everything you need to know about andropause - PINKVILLA - July 25th, 2020
- Impact of Covid-19 on Male Hypogonadism market 2020 | What are the key challenges to the Industry growth? - Bulletin Line - July 25th, 2020
- Male Hypogonadism Market expected to Witness a Sustainable Growth over 2017 - 2026 - Techinfeed - July 7th, 2020
- Steroids Know Factors Driving The Market to Record Growth - Daily Research Chronicles - July 7th, 2020
- Male Hypogonadism Market and Demand for COVID-19 Market Growth Projected to Amplify By 2027 | Eli Lilly and Company, Endo International, Merck &... - July 4th, 2020
- No fountain of youth: Just because theres a way to boost testosterone doesnt mean you should, experts warn - Gadsden Times - June 25th, 2020
- QOL and body composition benefits seen with novel oral T treatment - Urology Times - June 15th, 2020
- Novel oral testosterone therapy shows liver health benefits - Urology Times - June 15th, 2020
- Male Hypogonadism Therapy Market Business Analysis 2020 by Leading Industrial Source, Statistics, Gross Margin, Upstream Analysis, Downstream Analysis... - June 15th, 2020
- Male Hypogonadism Market Future Growth by In Depth Industry Analysis, Size, Trends and Forecast to 2026 - Cole of Duty - June 11th, 2020
- COVID-19 Update: Global Transdermal Testosterone Market is Expected to Grow at a Healthy CAGR with Top players: AbbVie, Teva, Perrigo, Endo... - June 11th, 2020
- Male Hypogonadism Therapy Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty - June 8th, 2020
- Male Hypogonadism Market to Witness a Healthy YoY Growth during 2017 2026 - Personal Injury Bureau UK - June 8th, 2020
- Jacobs School appoints new chair of Obstetrics and Gynecology - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter - June 8th, 2020
- Transdermal Testosterone Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026| - Jewish Life News - May 31st, 2020
- Male Hypogonadism Market Future Aspect Analysis and Current Trends by 2017 to 2025 - 3rd Watch News - May 24th, 2020
- Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone Therapy - Yahoo Finance - May 24th, 2020
- The Economic Impact of Coronavirus on Male Hypogonadism Market Analysis and Value Forecast Snapshot by End-use Industry 2019-2021 - 3rd Watch News - May 24th, 2020
- Men with Hypogonadism Leading to Low Testosterone Levels are More Likely to Die From the Coronavirus, Study Fi - Science Times - May 17th, 2020
- COVID-19 Testing Continues to Lift Aytu BioScience Stock - 24/7 Wall St. - May 17th, 2020
- Male Hypogonadism Therapy Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 - Cole of Duty - May 9th, 2020
- The impact of the coronavirus on the Male Hypogonadism Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 20582019-2019 - Jewish Life News - May 5th, 2020
- How Coronavirus Pandemic Will Impact Male Hypogonadism Market Poised for Steady Growth in the Future - Latest Herald - May 5th, 2020
- Male Hypogonadism Market Increasing Demand with Leading Key Players, Revenue Growth Analysis and Industry Share Price, Forecast 2025 - amitnetserver - May 5th, 2020
- Global trade impact of the Coronavirus Male Hypogonadism Market Shares, Strategies and Forecast Worldwide, 2019-2026 - Cole of Duty - May 5th, 2020
- Addressing the potential impact of coronavirus disease (COVID-19) on Male Hypogonadism Therapy Market : Future Growth and Challenges Analyzed Aminet... - May 3rd, 2020
- Male Hypogonadism Market Key Players, Product and Production Information analys - News by aeresearch - April 30th, 2020
- Hormone Replacement Therapy (HRT) Market Growth Is Skyrocketing Beyond Predictions - Express Journal - April 30th, 2020
- Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market to Surpass US$ 99,772.2 Million by 2027 - CMI - GlobeNewswire - April 28th, 2020
- The impact of the coronavirus on the Male Hypogonadism Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 20682019-2019 - Jewish Life News - April 25th, 2020
- The impact of the coronavirus on the Male Hypogonadism Market Solid Analyzed Segmentation, Demand, Recent Share Estimation and Growth Prospects by... - April 24th, 2020
- Male Hypogonadism Therapy Market Analysis by Size, Share, Top Key Manufacturers, Demand Overview, Regional Outlook And Growth Forecast to 2026 Cole... - April 24th, 2020
- Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market to Surpass US$ 99,772.2 Million by 2027 - CMI - Yahoo Finance - April 24th, 2020
- Global Male Hypogonadism Market 2019 Comprehensive Study with On-Going Trends, Majors Players and Forecast 2025 - Northwest Trail - April 22nd, 2020
- Low T Center Is Committed To Meeting The Needs Of Colorado Patients During The COVID-19 Emergency - The Grand Junction Daily Sentinel - April 18th, 2020
- Aytu BioScience Confirms Export and Incoming Delivery of COVID-19 IgG/IgM Rapid Tests - Yahoo Finance - April 18th, 2020
- What is testosterone replacement therapy, and do you need it - KTAR.com - March 31st, 2020
- Alcohol Consumption Linked to Lower Bone Formation Markers in Patients With HIV - Infectious Disease Advisor - March 23rd, 2020
- Aytu BioScience Expands Its Distribution Rights for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test to Canada and Mexico - Yahoo Finance - March 20th, 2020
- FDA: Thousands of Deaths Associated With Drugs Given to 'Trans' Children - Catholic Citizens of Illinois - March 20th, 2020
- Aytu BioScience Announces Acceleration of U.S. Availability of COVID-19 IgG/IgM Rapid Test Based on Updated FDA Policy - Yahoo Finance - March 18th, 2020
- CLARUS THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT THE COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE... - March 16th, 2020
- Aytu BioScience's Coronavirus Rapid Test Featured on NBC and Fox News (VIDEOS): ''Englewood Company Says It Can Get COVID-19 Test Results in 2-10... - March 16th, 2020
- Long-term Opioid Use in Men Linked to Hypogonadism - Medscape - March 15th, 2020